BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25896534)

  • 1. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis.
    Julià A; Fernandez-Nebro A; Blanco F; Ortiz A; Cañete JD; Maymó J; Alperi-López M; Fernández-Gutierrez B; Olivè A; Corominas H; Erra A; Acosta-Colman I; Alonso A; López-Lasanta M; Tortosa R; Tornero J; Marsal S
    Pharmacogenomics J; 2016 Apr; 16(2):147-50. PubMed ID: 25896534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis.
    Aterido A; Cañete JD; Tornero J; Blanco F; Fernández-Gutierrez B; Pérez C; Alperi-López M; Olivè A; Corominas H; Martínez-Taboada V; González I; Fernández-Nebro A; Erra A; López-Lasanta M; López Corbeto M; Palau N; Marsal S; Julià A
    Front Immunol; 2019; 10():1459. PubMed ID: 31312201
    [No Abstract]   [Full Text] [Related]  

  • 3. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.
    Umiċeviċ Mirkov M; Cui J; Vermeulen SH; Stahl EA; Toonen EJ; Makkinje RR; Lee AT; Huizinga TW; Allaart R; Barton A; Mariette X; Miceli CR; Criswell LA; Tak PP; de Vries N; Saevarsdottir S; Padyukov L; Bridges SL; van Schaardenburg DJ; Jansen TL; Dutmer EA; van de Laar MA; Barrera P; Radstake TR; van Riel PL; Scheffer H; Franke B; Brunner HG; Plenge RM; Gregersen PK; Guchelaar HJ; Coenen MJ
    Ann Rheum Dis; 2013 Aug; 72(8):1375-81. PubMed ID: 23233654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept.
    Ferreiro-Iglesias A; Montes A; Perez-Pampin E; Cañete JD; Raya E; Magro-Checa C; Vasilopoulos Y; Caliz R; Ferrer MA; Joven B; Carreira P; Balsa A; Pascual-Salcedo D; Blanco FJ; Moreno-Ramos MJ; Manrique-Arija S; Ordoñez MDC; Alegre-Sancho JJ; Narvaez J; Navarro-Sarabia F; Moreira V; Valor L; Garcia-Portales R; Marquez A; Gomez-Reino JJ; Martin J; Gonzalez A
    PLoS One; 2019; 14(2):e0213073. PubMed ID: 30818333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Variations in Pattern Recognition Receptor Loci Are Associated with Anti-TNF Response in Patients with Rheumatoid Arthritis.
    Sode J; Vogel U; Bank S; Andersen PS; Hetland ML; Locht H; Heegaard NH; Andersen V
    PLoS One; 2015; 10(10):e0139781. PubMed ID: 26440629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
    Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis.
    Cui J; Stahl EA; Saevarsdottir S; Miceli C; Diogo D; Trynka G; Raj T; Mirkov MU; Canhao H; Ikari K; Terao C; Okada Y; Wedrén S; Askling J; Yamanaka H; Momohara S; Taniguchi A; Ohmura K; Matsuda F; Mimori T; Gupta N; Kuchroo M; Morgan AW; Isaacs JD; Wilson AG; Hyrich KL; Herenius M; Doorenspleet ME; Tak PP; Crusius JB; van der Horst-Bruinsma IE; Wolbink GJ; van Riel PL; van de Laar M; Guchelaar HJ; Shadick NA; Allaart CF; Huizinga TW; Toes RE; Kimberly RP; Bridges SL; Criswell LA; Moreland LW; Fonseca JE; de Vries N; Stranger BE; De Jager PL; Raychaudhuri S; Weinblatt ME; Gregersen PK; Mariette X; Barton A; Padyukov L; Coenen MJ; Karlson EW; Plenge RM
    PLoS Genet; 2013 Mar; 9(3):e1003394. PubMed ID: 23555300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis.
    Honne K; Hallgrímsdóttir I; Wu C; Sebro R; Jewell NP; Sakurai T; Iwamoto M; Minota S; Jawaheer D
    Arthritis Res Ther; 2016 Jan; 18():12. PubMed ID: 26776603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
    Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
    J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis.
    Avila-Pedretti G; Tornero J; Fernández-Nebro A; Blanco F; González-Alvaro I; Cañete JD; Maymó J; Alperiz M; Fernández-Gutiérrez B; Olivé A; Corominas H; Erra A; Aterido A; López Lasanta M; Tortosa R; Julià A; Marsal S
    PLoS One; 2015; 10(4):e0122088. PubMed ID: 25848939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis.
    Acosta-Colman I; Palau N; Tornero J; Fernández-Nebro A; Blanco F; González-Alvaro I; Cañete JD; Maymó J; Ballina J; Fernández-Gutiérrez B; Olivé A; Corominas H; Erra A; Canela-Xandri O; Alonso A; López Lasanta M; Tortosa R; Julià A; Marsal S
    Pharmacogenomics; 2013 May; 14(7):727-34. PubMed ID: 23651021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis.
    Santos-Moreno P; Sánchez G; Gómez D; Bello-Gualtero J; Castro C
    J Clin Rheumatol; 2016 Mar; 22(2):57-62. PubMed ID: 26886438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
    Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
    BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study.
    Berghen N; Teuwen LA; Westhovens R; Verschueren P
    Clin Rheumatol; 2015 Oct; 34(10):1687-95. PubMed ID: 26219489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VARIAR Study: Assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist.
    Torrente-Segarra V; Acosta Pereira A; Morla R; Ruiz JM; Clavaguera T; Figuls R; Corominas H; Geli C; Roselló R; de Agustín JJ; Alegre C; Pérez C; García A; Rodríguez de la Serna A
    Reumatol Clin; 2016; 12(6):319-322. PubMed ID: 26831256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.